1. Home
  2. BAK vs GPCR Comparison

BAK vs GPCR Comparison

Compare BAK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$2.93

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$68.34

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAK
GPCR
Founded
1972
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BAK
GPCR
Price
$2.93
$68.34
Analyst Decision
Hold
Strong Buy
Analyst Count
2
11
Target Price
$4.40
$97.90
AVG Volume (30 Days)
784.0K
2.4M
Earning Date
11-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,841,708,237.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$13.22
52 Week High
$5.10
$94.90

Technical Indicators

Market Signals
Indicator
BAK
GPCR
Relative Strength Index (RSI) 51.52 68.61
Support Level $2.78 $61.87
Resistance Level $3.13 $72.00
Average True Range (ATR) 0.12 7.83
MACD -0.00 0.38
Stochastic Oscillator 51.09 48.10

Price Performance

Historical Comparison
BAK
GPCR

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: